WO2004113381A1 - Relaxin superfamily peptide analogues - Google Patents
Relaxin superfamily peptide analogues Download PDFInfo
- Publication number
- WO2004113381A1 WO2004113381A1 PCT/AU2004/000798 AU2004000798W WO2004113381A1 WO 2004113381 A1 WO2004113381 A1 WO 2004113381A1 AU 2004000798 W AU2004000798 W AU 2004000798W WO 2004113381 A1 WO2004113381 A1 WO 2004113381A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analogue
- relaxin
- disorder
- disorders
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to generally to conformationally constrained, monomeric peptide analogues of the relaxin superfamily of heteromeric proteins and in particular, to monomeric cyclic analogues of the B-chain of relaxin superfamily proteins, methods of making these analogues, and uses thereof.
- the relaxin superfamily currently comprises 10 members with a relatively high degree of sequence homology. These family members include insulin, insulin-like grown factors I and II, relaxin 1, 2 and 3, and the insulin-like hormones INSL3, 4, 5 and 6.
- the relaxin superfamily members have a wide range of biological activities which are well described in the art.
- Insulin has a key role in cellular metabolism. Many subjects with diabetes require daily administration of insulin.
- Relaxin is an insulin-like peptide having two separate chains (A and B) joined by two interchain and one intrachain disulfide bond.
- the actions of relaxin include an ability to inhibit myometrial contractions, stimulation of remodelling of connective tissue and induction of softening of the tissues of the birth canal. Additionally, relaxin increases growth and differentiation of the mammary gland and nipple and induces the breakdown of collagen, one of the main components of connective tissue. Relaxin decreases collagen synthesis and increases the release of collagenases (Unemori et al (1990) J. Biol. Chem.
- relaxin is more than a hormone of pregnancy and acts on cells and tissues other than those of the female reproductive system.
- Relaxin causes a widening of blood vessels (vasodilatation) in the kidney, mesocaecum, lung and peripheral vasculature, which leads to increased blood flow or perfusion rates in these tissues (Bani et al (1997) Gen. Pharmacol. 28, 13-22). It also stimulates an increase in heart rate and coronary blood flow, and increases both glomerular filtration rate and renal plasma flow (Bani et al (1997) Gen. Pharmacol. 28, 13-22).
- Relaxin has also been found to inhibit histamine release and the accumulation of calcium, as well as promote nitric oxide synthesis, during cardiac anaphylaxis (Masini et al, Br J Pharmacol. 2002 Oct;137(3):337-44).
- the brain is another target tissue for relaxin where the peptide has been shown to bind to receptors (Osheroff et al (1991) Proc. Nal Acad. Sci. U.S.A. 88, 6413-6417; Tan et al (1999) Br. J. Pharmacol 127, 91-98) in the circumventricular organs to affect blood pressure and drinking (Parry et al (1990) J Neuroendocrinol. 2, 53-58; Summerlee et al (1998) Endocrinology 139, 2322-2328; Sinnahay et al (1999) Endocrinology 140, 5082-5086).
- relaxin in various diseases responding to fibrotic breakdown, connective tissue remodelling, scleroderma, vasodilation, such as coronary artery disease, peripheral vascular disease, kidney disease associated with arteriosclerosis or other narrowing of kidney capillaries, or other capillaries nanowing in the body, such as in the eyes or in the peripheral digits, the mesocaecum, lung and peripheral vasculature, and neurological modification.
- Relaxin has also been implicated in depression of platelet aggregation and their release by megakaryocytes, and may thus be associated with clotting disorders.
- the INSL peptides may be involved in various physiological actions, including descent of the gonads.
- L SL3 has been shown to be involved in maturation and descent of the testes (Ivell & Hartnung, Mol Hum Reprod 2003, 9(4): 175- 181), as well as the survival of sperm cells, development of ovarian follicles and maturation of the oocyte (Kawamura et al, 2004, PNAS 101, 7323-7328). Therefore, potential clinical applications of L SL3 agonists and antagonists include the treatment of fertility disorders, or the control of fertility levels.
- INSL3 has been implicated in regulation of relaxin activity in the heart (Tan et al, Eur J Pharmacol. 2002 Dec 20;457(2-3): 153-60), and may thus play an important regulatory role in cardiovascular disease.
- INSL3 polymorphisms have been hyperplastic and neoplastic disorders of the thyroid gland (Hombach-Klonisch et al., Lit J Oncol 2003 May; 22(5): 993-1001), suggesting a role for this relaxin superfamily member in the etiology of these pathologies.
- LGR7 is the relaxin receptor, which binds all human relaxin peptides with high affinity, but has very low affinity for LNSL3 (Bathgate et al., Trends in Endocrinology and Metabolism 2003, 14: 207-213).
- LGR8 is the LNSL3 receptor, which binds INSL3 with high affinity. Knockout mice which lack a LGR8 gene have identical phenotype to the INSL3 knockout mice. However in the human, LGR8 will also bind relaxin, although it has a higher affinity for L SL3 (Bathgate et al., Trends in Endocrinology and Metabolism 2003, 14: 207-213).
- the LGR8 receptor is expressed in the gubernaculum, ovary and testis, where in the latter organ it mediates LNSL3's actions on testes descent (Bathgate et al, Trends in Endocrinology and Metabolism 2003, 14: 207-213). In the ovary, LGR8 mediates foUicular development and in both the testes and ovaries, it is implicated in male and female germ-cell maturation (Kawamura et al, 2004, PNAS 101, 7323-7328). LGR8 is also expressed in the kidney, bone, peripheral-blood leucocytes, muscle, brain, thyroid, and uterus (Hsu et al, Science, 295: 671-674).
- LNSL3 has potential actions on kidney and thyroid function, central actions on the brain, modulation of muscle function, effects on bone and blood cell function and reproductive actions on the uterus.
- analogues that are relaxin-superfamily analogues which bind at the biological receptors for the relaxin superfamily proteins.
- such analogues would include ligands, such as agonists, reverse agonists, partial agonists, mixed agonists/antagonists and full antagonists, which bind at the relaxin superfamily member receptors and initiate, inhibit, activate, or otherwise control, the biological activities of members of this protein superfamily.
- Analogues of the relaxin superfamily proteins could provide the opportunity for a wide range of therapeutic interventions.
- the present invention relates to peptide analogues of members of the relaxin superfamily of proteins, the analogues having a binding activity at a relaxin protein superfamily receptor, methods of producing the analogues, and pharmaceutical compositions, methods of treatment, and uses of the peptide analogues.
- the analogue is a conformationally constrained, monomeric cyclic peptide analogue of a B-chain of a relaxin superfamily member protein which binds to a biological target of the relaxin superfamily protein, the protein being selected from insulin, IGF-I, IGF-II, relaxin 1, relaxin 2, relaxin 3, TNSL3, L SL4, LNSL5 or INSL6.
- the monomeric peptide analogues of the invention are produced by modification of a turn or loop moiety of the B-chain of the relaxin superfamily protein, the modification involving selection of at least a first and a second amino acid residue with an alpha-helix or beta-strand carbon separation distance of less than six Angstroms and cross-linking the first and second amino acids, wherein the cross-link conformationally constrains the analogue.
- the monomeric analogue is an INSL3 B-chain analogue modified from the sequence set forth in SEQ ID NO:7.
- the LNSL3 analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequences set forth in SEQ TD NO:7.
- the first and/or second amino acids are substituted with amino acids suitable for cross-linking.
- the monomeric analogue is the LNSL3 analogue designated c ⁇ SLa in Figure 3.
- the monomeric analogue is the INSL3 analogue designated cTNSLb in Figure 3.
- the monomeric analogue is a relaxin analogue modified from a relaxin-1, relaxin-2, or relaxin-3 B-chain sequence set forth in SEQ TD NOs: 1, 2 and 3, respectively.
- the monomeric relaxin analogue is the relaxin analogue designated cRlx in Figure 3.
- the monomeric relaxin analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequences set forth in SEQ LD NO:2.
- one or more amino acids within the INSL3 or relaxin peptide analogue sequence, other than the cross-linked first and second amino acids, is optionally substituted to modify one or more biological activities of the monomeric analogue.
- the monomeric analogue is an agonist, partial agonist, antagonist, partial antagonist or reverse antagonist at the relaxin superfamily receptor.
- analogues of the invention are conjugated to an A-chain of the relaxin superfamily protein.
- the monomeric analogues of the invention are conjugated to carrier molecules, such as labelling compounds, radioligands, radionucleotides, i munotherapeutic agents or other desirable chemical moiety.
- the invention seeks to provide a method of making a monomeric peptide analogue of a relaxin superfamily protein, the method comprising: - providing a B-chain, receptor-binding subunit of a relaxm superfamily protein; and
- first and/or second amino acids are substituted with amino acids suitable for cross linking.
- the method produces an LNSL3 peptide analogue based on the sequence set forth in SEQ ID NO:7.
- the method produces the INSL3 analogue designated c NSLa in Figure 3.
- the method produces the INSL3 analogue designated cINSLb in Figure 3.
- the method produces a monomeric relaxin-1, relaxin-2 or relaxin-3 peptide analogue based on any of the sequences set forth in SEQ ID NOs:l, 2 and 3, respectively.
- the method produces a monomeric relaxin analogue designated cRlx in Figure 3.
- the method produces an L SL3 and/or relaxin analogue wherein one or more amino acids other than the cross-linked first and second amino acids, are optionally substituted to modify one or more biological activities of the peptide analogue.
- composition including one or more of the monomeric analogues of the present invention, and pharmaceutically acceptable salts thereof.
- the phannaceutical composition includes an INSL3 analogue or a relaxin analogue.
- the disorder is characterised by disregulation of relaxin and/or LNSL3 expression or activity.
- the invention provides a method of treating, preventing or ameliorating the symptoms of a relaxin or INS L3 -mediated disorder in a patient, wherein the disorder is selected from the group consisting of hyperplastic disorders, neoplastic disorders, scleroderma, uncontrolled or abnormal collagen or fibronectin formation or breakdown, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, inflammatory bowel disease, Raynaud's disease, Raynaud's phenomenon, cryptorchidism, disregulation of spermatogenesis and reproductive development including descent of the gonads, the method comprising administering to the patient an effective amount of a peptide analogue of the invention.
- the invention contemplates the use of the analogues and/or pharmaceutical compositions of the present invention in the manufacture of a medicament for the treatment of a relaxin or INSL3 -mediated disorder in a patient, the disorder selected from the group consisting of: hyperplastic disorders, neoplastic disorders, scleroderma, uncontrolled or abnormal collagen or fibronectin formation or breakdown, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, inflammatory bowel disease, Raynaud's disease, Raynaud's phenomenon, cryptorchidism, disregulation of spermatogenesis and reproductive development including descent of the gonads.
- a relaxin or INSL3 -mediated disorder in a patient, the disorder selected from the group consisting of: hyperplastic disorders, neoplastic disorders, scleroderma, uncontrolled or abnormal collagen or fibronectin formation or breakdown, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, inflammatory
- FIGURE 1 Schematic representation of binding of TNSL3, cINSLa and cINSLb analogues to the LGR8 receptor.
- FIGURE 2 Schematic representation of binding of the relaxin-like or L SL3 analogues to the LGR7 receptor.
- FIGURE 3 Sequences and constraints of the native relaxin and L SL3-B chains with exemplary analogues designed.
- FIGURE 4 Schematic representation of antagonistic activity of cINSLa in the inhibition of the response of INSL3 (measured by cAMP response) to the native L SL3 receptor (LGR8).
- FIGURE 5 Schematic representation illustrating CD spectra of cINSLa showing significant alpha-helical content in water and phosphate buffered saline.
- the present invention relates to peptide analogues of members of the relaxin superfamily of proteins, the analogues having a binding activity at a relaxin protein superfamily receptor, methods of producing the analogues, and pharmaceutical compositions, methods of treatment, and uses of the peptide analogues.
- the analogue is a conformationally constrained, cyclic analogue of a B- chain of a relaxin superfamily member protein which binds to a biological target of a relaxin superfamily protein, and modulates an activity of the biological target, wherein the relaxin superfamily protein is selected from insulin, IGF-I, IGF-LI, relaxin 1, relaxin 2, relaxin 3, LNSL3, L SL4, INSL5 or LNSL6.
- the tenn “modulates” as used herein includes, but is not limited to, initiation of activity at a biological target of a relaxin superfamily protein, up- or down-regulation of activity at a biological target of a relaxin superfamily protein, or blockage of an activity at a biological target of a relaxin superfamily protein.
- the biological targets of relaxin superfamily proteins include receptors, such as but not limited to, LGR7, LGR8, GPCR135, GPCR142, the insulin receptor, the IGF-1 receptor, and the IGF-II receptor.
- the analogue can also be a ligand at a relaxin superfamily receptor, wherein the analogue ligand can have an activity including, but not limited to, that of an agonist, antagonist, mixed agonist, reverse agonist, partial agonist, partial antagonist or reverse antagonist at the receptor.
- the cyclic B-chain peptide analogues of the invention are produced by modification of a turn or loop moiety of the B-chain of the relaxin superfamily protein, the modification involving selection of at least a first and a second amino acid residue with an alpha-helix or beta-strand carbon separation distance of less than six Angstroms and cross-linking the first and second amino acids, wherein the cross-link conformationally constrains the analogue.
- the analogue is an LNSL3 B-chain analogue modified from the sequence set forth in SEQ ID NO:7.
- the L SL3 analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequences set forth in SEQ LD NO:7.
- the INSL3 analogue is constrained by a cross-link between a first amino acid witliin a range of positions 2 and 8, including positions 2, 3, 4, 5, 6, 7, and 8, and a second amino acid within a range of positions 21 and 26, including 21, 22, 23, 24, 25 and 26, of the sequence set forth in SEQ ED NO:7.
- the B-chain peptide analogue is the LNSL3 analogue designated cINSLa in Figure 3.
- the B-chain peptide analogue is the INSL3 analogue designated cINSLb in Figure 3.
- the analogue is a relaxin analogue modified from a relaxin-1, relaxin-2, or relaxin-3 B-chain sequence set forth in SEQ LD NOs: 1, 2 and 3, respectively.
- the relaxin analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequences set forth in SEQ ID NO:2.
- the relaxin analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8, including positions 2, 3, 4, 5, 6, 7, and 8, and a second amino acid within a range of positions 21 and 26, including 21, 22, 23, 24, 25 and 26, of the sequence set forth in SEQ ID NO:2.
- the B-chain analogue is the relaxin analogue designated CRlx in Figure 3.
- the first and second amino acids are substituted with amino acids suitable for cross linking.
- Suitable chemical linking groups have 0 to 20 carbon atoms, 0 to 10 heteroatoms (N,0, S, P etc.), and can be straight chain or branched an contain saturated, unsaturated and/or aromatic rings, single and/or double bonds and chemical groups such as amide, ester, disulfide, thioether, ether, phosphate, amine and the like.
- the amino-acid substitution and fonnation of a cross-link, which is used to conformationally constrain the B-chain can be obtained by several methods, including but not limited to: (i) cyclizing the N-terminal amine with the C-terminal carboxyl acid function, either directly via an amide bond between the N-terminal nitrogen and C-terminal carbonyl, or indirectly via a spacer group, for example by condensation with an M-amino carboxylic acid; (ii) cyclizing via the formation of a covalent bond between the side chains of two residues, such as an amide bond between a lysine residue and either an aspartic acid or glutamic acid residue, or a disulfide bond between two cysteine residues, or a thioether bond between a cysteine residue and anz-halogenated amino acid residue, either directly or via a spacer group as described in (i) above.
- the residues contributing the side chains may be derived from the B-chain sequence itself, or may be
- the B-chain peptide analogue can be made in which one or more amino acid residues is replaced by its corresponding D-amino acid, substitutions or modifications are made to one or more amino acids in the sequence, peptide bonds can be replaced by a structure more resistant to metabolic degradation and different cyclizing constraints and dimerization groups can be incorporated.
- Analogues of the invention can also be made where individual amino acids are replaced by analogous structures, for example gem-diaminoalkyl groups or alkylmalonyl groups, with or without modified termini or alkyl, acyl or amine substitutions to modify their charge.
- analogous structures for example gem-diaminoalkyl groups or alkylmalonyl groups, with or without modified termini or alkyl, acyl or amine substitutions to modify their charge.
- the use of such alternative structures can provide significantly longer half-life in the body, since they are more resistant to breakdown under physiological conditions.
- the substitution is conservative, i.e. an amino acid is replaced by one of similar size and with similar charge properties.
- conservative substitution denotes the replacement of an amino acid residue by another, biologically similar residue.
- conservative substitutions include the substitution of one hydrophobic residue such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine, and the like.
- Neutral hydrophilic amino acids which can be substituted for one another include asparagine, glutamine, serine and threonine.
- conservative substitution also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid.
- conservative amino acids can be grouped as described in Lehninger, [Biochemistry, Second Edition; Worth Publishers, Inc. NY: NY(1975), pp. 71-77] as set out in the following Table B.
- cyclic peptide analogues of the invention can be modified, for instance, by glycosylation, amidation, carboxylation, or phosphorylation, or by the creation of acid addition salts, amides, esters, in particular C-terminal esters, and N-acyl derivatives of the peptides of the invention.
- the peptide analogues also can be modified to create peptide derivatives by forming covalent or noncovalent complexes with other moieties.
- Covalently-bound complexes can be prepared by cross-linking the chemical moieties to functional groups on the side chains of amino acids comprising the peptides, or at the N-or C tenninus.
- the B-chain peptide analogues can be conjugated to an A-chain of a relaxin superfamily protein, and preferably, the A-chain of the relaxin superfamily protein to which they share B-chain analogy.
- the B-chain peptide analogues can be conjugated to a reporter group, including, but not limited to a radiolabel, a fluorescent label, an enzyme (e.g., that catalyzes a colorimetric or fluorometric reaction), a substrate, a solid matrix, or a carrier (e. g., biotin or avidin).
- a reporter group including, but not limited to a radiolabel, a fluorescent label, an enzyme (e.g., that catalyzes a colorimetric or fluorometric reaction), a substrate, a solid matrix, or a carrier (e. g., biotin or avidin).
- one or more amino acids within the peptide analogue sequence, other than the first and second amino acids, is optionally substituted to modify one or more biological activities of the analogue.
- biological activities includes, but is not limited to, binding affinity for a biological target, effector activity at the biological target and in vivo stability.
- the invention seeks to provide a method of making a peptide analogue of a relaxin superfamily protein, the method comprising:
- the first and second amino acids are substituted with amino acids suitable for cross linking.
- the method produces an INSL3 peptide analogue based on the sequence set forth in SEQ ID NO:7.
- the method produces an INSL3 analogue designated cRlx, cL SL3a or cINSL3b in Figure 3.
- the method produces a relaxin-1, relaxin-2 or relaxin-3 peptide analogue based on any of the sequences set forth in SEQ ED NOs:l, 2 and 3, respectively.
- the method produces a relaxin analogue designated cRlx in Figure 3.
- the method produces an LNSL3 and/or relaxin analogue wherein one or more amino acids other than the cross-linked first and second amino acids, are optionally substituted to modify one or more biological activities of the peptide analogue.
- One aspect of the invention utilises the ability of the B-chain peptide analogues of the invention to modulate an activity of a biological target of at least one relaxin superfamily protein member, that is, induce or modify an activity of at least one relaxin superfamily protein member, and in particular, relaxin or INSL3, which are mediated through the actions of the LGR7 or LGR8 receptors.
- the analogues can thus induce an activity of a relaxin superfamily member, in the absence of endogenous expression of the protein, or suppress or antagonise the activity of a protein endogenously expressed.
- the analogues of the invention can up-regulate the level of an existing biological activity of a relaxin superfamily member.
- Such biological activities include, but are not limited to, collagen degradation and remodelling, vascular dilation, growth and differentiation of the mammary gland, increased blood flow and organ perfusion, increasing heart rate, increasing coronory blood flow, increasing glomerular filtration rate and renal plasma flow, maturation of the gonads, promotion of cellular division, survival of sperm cells, development of ovarian follicles and oocyte maturation.
- LGR8 is also expressed in the kidney, bone, peripheral blood leukoctyes, muscle, brain, thyroid, and uterus.
- INSL3 analogues have potential actions on kidney and thyroid function, central actions on the brain, modulation of muscle function, effects on bone and blood cell function and reproductive actions on the uterus.
- modification of any one or more of the above-mentioned biological activities of the relaxin superfamily proteins requires administration of an effective, biological- activity interfering amount of a B-chain analogue of the invention.
- Clinical applications of the invention include, but are not limited to, hyperplastic disorders, neoplastic disorders, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, inflammatory bowel disease, Raynaud's disease, Raynaud's phenomenon, cryptorchidism, disregulation of spermatogenesis, male and female infertility and reproductive development including descent of the gonads.
- composition including one or more of the analogues of the present invention, and pharmaceutically acceptable salts thereof.
- Another aspect of the invention concerns the provision of a pharmaceutical composition
- a pharmaceutical composition comprising a B-chain analogue of the invention, and a pharmaceutically acceptable non- toxic salt thereof, and a pharmaceutically acceptable solid or liquid carrier or adjuvant.
- a preferred pharmaceutical composition will inhibit or interfere with a biological activity induced by at least one member of a relaxin superfamily protein.
- a particularly preferred pharmaceutical composition will inhibit the biological activity induced by relaxin and/or INSL3.
- Such a carrier or adjuvant examples include, but are not limited to, saline, buffered saline, Ringer's solution, mineral oil, talc, corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, alginic acid, dextrose, water, glycerol, ethanol, thickeners, stabilizers, suspending agents and combinations thereof.
- Such compositions may be in the form of solutions, suspensions, tablets, capsules, creams, salves, elixirs, syrups, wafers, ointments or other conventional forms.
- compositions comprising a peptide of the invention will contain from about 0. 1% to 90% by weight of the active compound(s), and most generally from about 10% to 30%.
- the dose(s) and route of administration will depend upon the nature of the patient and condition to be treated, and will be at the discretion of the attending physician or veterinarian.
- Suitable routes include oral, subcutaneous, intramuscular, intraperitoneal or intravenous injection, parenteral, topical application, implants etc.
- an effective amount of a monomeric monocyclic peptide of the invention or a dimeric bicyclic peptide of the invention is administered to an organism in need thereof in a dose between about 0.1 and lOOOjLtg/kg body weight.
- the B-chain analogues of the invention may be used as therapeutic compositions either alone or in combination with other therapeutic agents.
- the pharmaceutical composition includes an L SL3 analogue or a relaxin analogue.
- the disorder is characterised by disregulation of relaxin and/or LNSL3 expression or activity.
- relaxin binds to at least two biological targets: LGR7 and LGR8, while INSL3 appears to mediate its biological effects via LGR8 only.
- an analogue with relaxin-like binding activity which exhibits affinity for LGR7 and LGR8 will modulate the effects of both relaxin and INSL3, given that LNSL3 shares a common receptor with relaxin.
- LGR8 binds both relaxin and INSL3
- many of relaxin' s effects are modulated by INSL3 levels, and vice versa.
- the invention provides a method of treating, preventing or ameliorating the symptoms of a relaxin or INSL3 -mediated disorder in a patient, the disorder selected from the group consisting of hyperplastic disorders, neoplastic disorders, scleroderma, uncontrolled or abnormal collagen or fibronectin formation or breakdown, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, male and female infertility, inflammatory bowel disease, Raynaud's disease, Raynaud's phenomenon, cryptorchidism, disregulation of spermatogenesis and reproductive development including descent of the gonads, the method comprising administering to the patient an effective amount of a peptide of the invention.
- the disorder selected from the group consisting of hyperplastic disorders, neoplastic disorders, scleroderma, uncontrolled or abnormal collagen or fibronectin formation or breakdown, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, male and female infertility,
- condition associated with pregnancy includes, but is not limited to, conditions of fertilisation, pregnancy, parturition and lactation.
- the term “relaxin or INSL3 -mediated” as used herein refers to conditions where relaxin or INSL3 are involved or implicated in the development, maintenance or progression of the condition.
- the invention contemplates the use of the analogues and/or pharmaceutical compositions of the present invention in the manufacture of a medicament for the treatment of a relaxin or INSL3 -mediated disorder in a patient, the disorder selected from the group consisting of: hyperplastic disorders, neoplastic disorders, scleroderma, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, male and female infertility, inflammatory bowel disease, Raynaud's disease, Raynaud's phenomenon, cryptorchidism, disregulation of spermatogenesis and reproductive development including descent of the gonads.
- a relaxin or INSL3 -mediated disorder in a patient, the disorder selected from the group consisting of: hyperplastic disorders, neoplastic disorders, scleroderma, neurological disorders, angiogenic disorders, cardiovascular disorders, female reproductive disorders, conditions associated with pregnancy, renal disease, male and female infertility, inflammatory bowel disease, Raynaud's disease,
- a second cyclic analogue cINSLb was formed by changing His 12 to Arg, to mimic a relaxin-like binding motif of Arg-X-X-Arg-X-X-X-Nal.
- the synthesis of the INSL3 analogues were achieved using the continuous flow Fmoc- methodology as previously described (Dawson et al, J Peptide Res 53:542-547, 1999).
- the solid support was Fmoc-PAL PEG-PS (PerSeptive Biosystems, USA), and HBTU-- activated Fmoc-amino acids were used throughout..
- N ⁇ -Fmoc deprotection was with 20% piperidine in DMF. All derivatives were purchased from Auspep (Melbourne, Australia).
- the purity of the synthetic peptide was assessed by analytical RP-HPLC, and matrix- assisted laser desorption time of flight (MALDITOF) mass spectrometry using a Bruker Biflex instrument (Bremen, Germany) in the linear mode at 19.5 kN.
- Peptide quantitation was by amino acid analysis of a 24 hour acid hydrolyzate using a GBC instrument (Melbourne, Australia).
- CD spectra were taken on a Jasco J-720 instrument at room temperature in a 1 mm path- length cell, Doubly distilled water, 10 mM sodium phosphate buffer containing 120 mM ⁇ aCI pH 7.4, and spectroscopy grade trifluoroethanol (TFE) were used as solvents.
- the peptide concentrations were made to l ⁇ M, determined by quantitative RP-HPLC and amino acid analysis (ref). Curves were smoothed by the algorithm provided by Jasco, Mean residue ellipticity ([ ⁇ ] R ) is expressed in degrees x cm2/dmole by using the molecular mass.
- CD spectra evaluations were based on comparison with known peptide conformations (Otvos, L., Jr. 1996. from ⁇ europeptide protocols. Irvine, G. & Williams, C, Eds. pp 153-161. Humana Press, Totowa, ⁇ J).
- Human 293T cells stably transfected with human LGR7, or LGR8 were preincubated in the presence of 0.25mM 3 -isobutyl-1 -methyl xanthine (TJBMX, Sigma) before various treatments for 30 minutes. At the end of the incubation cells were lysed for measurement of cAMP using a well-characterized cAMP ELISA (Satoko et al, JBiol Chem, 278:7855- 7862). All experiments were repeated at least three times using cells from independent transfections, Results are plotted as pmol cAMP/10 4 cells.
- Ligand binding assays The method for binding of 33P-labelled relaxin to 293T cells stably transfected with either LGR7 or LGR8 has been described previously (Satoko et al, J Biol Chem, 278:7855- 7862). Data are expressed as mean ⁇ SEM of % specific binding of triplicate determinations performed on a least three independent plates of transfected cells. Data were plotted using the one-site competition functions of the PRISM program (Graphpad Inc., San Diego, USA).
- cINSLb was a INSL3 -based sequence, in which Hisl2 form the INSL3 sequence was replaced by Arg in an attempt to obtain an analogue of the putative relaxin receptor binding cassette which if absent in INSL3.
- the same approach is used to prepare insulin B chain analogues and other relaxin superfamily analogues.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ544216A NZ544216A (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
AU2004249329A AU2004249329B2 (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
AT04737019T ATE474850T1 (en) | 2003-06-20 | 2004-06-18 | ANALOGUES OF PEPTIDES OF THE RELAXIN SUPERFAMILY |
CA2534748A CA2534748C (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
US10/561,304 US20070004619A1 (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
EP04737019A EP1641824B1 (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
DE602004028246T DE602004028246D1 (en) | 2003-06-20 | 2004-06-18 | ANALOGUE OF PEPTIDES OF THE RELAXIN SUPERFAMILY |
JP2006515545A JP2007534613A (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003903124A AU2003903124A0 (en) | 2003-06-20 | 2003-06-20 | Analogues of heteromeric proteins |
AU2003903124 | 2003-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004113381A1 true WO2004113381A1 (en) | 2004-12-29 |
Family
ID=31954163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2004/000798 WO2004113381A1 (en) | 2003-06-20 | 2004-06-18 | Relaxin superfamily peptide analogues |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070004619A1 (en) |
EP (1) | EP1641824B1 (en) |
JP (1) | JP2007534613A (en) |
AT (1) | ATE474850T1 (en) |
AU (1) | AU2003903124A0 (en) |
CA (1) | CA2534748C (en) |
DE (1) | DE602004028246D1 (en) |
NZ (1) | NZ544216A (en) |
WO (1) | WO2004113381A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553813B2 (en) | 2004-04-30 | 2009-06-30 | Corthera, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
EP2129359A2 (en) * | 2007-01-30 | 2009-12-09 | Janssen Pharmaceutica, N.V. | Chimeric peptide antagonist for gpcr135 or gpcr142 |
GR1006759B (en) * | 2008-12-22 | 2010-04-20 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras) | Improved chemical synthesis of human relaxin |
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US9359422B2 (en) | 2010-09-08 | 2016-06-07 | The University Of Queensland | Single chain relaxin polypeptides |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893197B2 (en) * | 2004-08-25 | 2011-02-22 | Janssen Pharmaceutica N.V. | Relaxin-3 chimeric polypeptides and their preparation and use |
US20060052304A1 (en) * | 2004-09-02 | 2006-03-09 | Bas Medical, Inc. | Method for remodeling bone and related sutures |
US8496446B2 (en) * | 2005-08-29 | 2013-07-30 | Carrier Corporation | Compressor muffler |
US20110072955A1 (en) | 2005-10-06 | 2011-03-31 | Turner William D | System and method for pacing repetitive motion activities |
US20100041603A1 (en) * | 2008-05-16 | 2010-02-18 | Corthera, Inc. | Method of Promoting Wound Healing |
KR20130036290A (en) | 2010-06-23 | 2013-04-11 | 노보 노르디스크 에이/에스 | Insulin derivatives containing additional disulfide bonds |
EP2585484A1 (en) * | 2010-06-23 | 2013-05-01 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
WO2011161083A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
BR112013003522B1 (en) * | 2010-08-17 | 2021-05-25 | Ambrx, Inc. | modified relaxin polypeptides comprising a non-naturally encoded amino acid, their method of preparation and their use, as well as nucleic acid and host cell |
JP2015502971A (en) * | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー/エス | N-terminal modified insulin derivative |
CN103456765B (en) | 2013-09-10 | 2015-09-16 | 深圳市华星光电技术有限公司 | Active organic electroluminescence device backboard and preparation method thereof |
CN110637027A (en) | 2017-02-08 | 2019-12-31 | 百时美施贵宝公司 | Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof |
CN114075276A (en) * | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | Long-acting relaxin 2 analogue |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0101309B1 (en) * | 1982-08-12 | 1991-01-16 | Howard Florey Institute Of Experimental Physiology And Medicine | Molecular cloning and characterization of a gene sequence coding for human relaxin |
NZ206534A (en) * | 1982-12-13 | 1988-05-30 | Florey Howard Inst | Molecular cloning and characterisation of gene sequence coding for human relaxin |
US4835251A (en) * | 1986-06-23 | 1989-05-30 | Genetech, Inc. | Method of chain combination |
US5911997A (en) * | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
AUPR814401A0 (en) * | 2001-10-08 | 2001-11-01 | Howard Florey Institute Of Experimental Physiology And Medicine | Human 3 relaxin |
-
2003
- 2003-06-20 AU AU2003903124A patent/AU2003903124A0/en not_active Abandoned
-
2004
- 2004-06-18 AT AT04737019T patent/ATE474850T1/en not_active IP Right Cessation
- 2004-06-18 CA CA2534748A patent/CA2534748C/en not_active Expired - Fee Related
- 2004-06-18 NZ NZ544216A patent/NZ544216A/en not_active IP Right Cessation
- 2004-06-18 US US10/561,304 patent/US20070004619A1/en not_active Abandoned
- 2004-06-18 JP JP2006515545A patent/JP2007534613A/en active Pending
- 2004-06-18 EP EP04737019A patent/EP1641824B1/en not_active Expired - Lifetime
- 2004-06-18 DE DE602004028246T patent/DE602004028246D1/en not_active Expired - Lifetime
- 2004-06-18 WO PCT/AU2004/000798 patent/WO2004113381A1/en active Application Filing
Non-Patent Citations (3)
Title |
---|
BULLESBACH E. ET AL.: "Semisynthesis with insulin-B-chain", CHEM. PEPT. PROTEINS, PROC. USSR-FRG SYMP. 3RD, vol. 1, 1982, pages 327 - 335, XP008063149 * |
BULLESBACH ERIKA ET AL.: "Preparation of partially protected des-alanineB30-insulin-B-chain-disulfide and its use in semisynthesis", INTERNATIONAL JOURNAL OF PEPTIDE & PROTEIN RESEARCH, vol. 20, no. 3, 1982, pages 207 - 217, XP008063150 * |
IVANOV CH. ET AL.: "Structure elucidation of the thiolated and oxidated B insulin chain by sephadex gel molecular weight determination", DOKLADY BOLGARSKOI AKADEMII NAUK, vol. 29, no. 11, 1976, pages 1641 - 1644, XP008063154 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
US8602998B2 (en) | 2004-03-18 | 2013-12-10 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of relaxin to increase arterial compliance |
US7553813B2 (en) | 2004-04-30 | 2009-06-30 | Corthera, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
US8026215B2 (en) | 2004-04-30 | 2011-09-27 | Corthera, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
EP2129359A2 (en) * | 2007-01-30 | 2009-12-09 | Janssen Pharmaceutica, N.V. | Chimeric peptide antagonist for gpcr135 or gpcr142 |
EP2129359A4 (en) * | 2007-01-30 | 2011-05-18 | Janssen Pharmaceutica Nv | Chimeric peptide antagonist for gpcr135 or gpcr142 |
US8299028B2 (en) | 2007-01-30 | 2012-10-30 | Janssen Pharmaceutica Nv | Chimeric peptide antagonist for GPCR135 or GPCR142 |
GR1006759B (en) * | 2008-12-22 | 2010-04-20 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras) | Improved chemical synthesis of human relaxin |
US9359422B2 (en) | 2010-09-08 | 2016-06-07 | The University Of Queensland | Single chain relaxin polypeptides |
Also Published As
Publication number | Publication date |
---|---|
AU2003903124A0 (en) | 2003-07-10 |
ATE474850T1 (en) | 2010-08-15 |
CA2534748A1 (en) | 2004-12-29 |
EP1641824A1 (en) | 2006-04-05 |
US20070004619A1 (en) | 2007-01-04 |
NZ544216A (en) | 2008-09-26 |
EP1641824A4 (en) | 2008-02-13 |
DE602004028246D1 (en) | 2010-09-02 |
EP1641824B1 (en) | 2010-07-21 |
JP2007534613A (en) | 2007-11-29 |
CA2534748C (en) | 2013-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2534748C (en) | Relaxin superfamily peptide analogues | |
AU766545B2 (en) | Novel anti-diabetic peptides | |
US4835251A (en) | Method of chain combination | |
US7928060B2 (en) | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them | |
US20030104981A1 (en) | Human insulin analogues | |
CA2722168A1 (en) | Isoform-specific insulin analogues | |
WO1996040185A1 (en) | Relaxin analogs and derivatives methods and uses thereof | |
EP2215114B1 (en) | Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides | |
CN112876552A (en) | Long-acting adrenomedullin derivative | |
CN116712530B (en) | Long-acting GLP-1/glucon/GIP receptor triple agonist and application thereof | |
CA3156847A1 (en) | Active polypeptide compound | |
WO2016172269A2 (en) | Insulin analogs having shortened b chain peptides and associated methods | |
CA2320962C (en) | Novel mixed amylin activity compounds | |
AU2004249329B2 (en) | Relaxin superfamily peptide analogues | |
AU2004249329A1 (en) | Relaxin superfamily peptide analogues | |
US6936584B1 (en) | Mixed amylin activity compounds | |
CN117624333A (en) | GLP-1 receptor, glucagon receptor and GIP receptor tri-excitation polypeptide compound and application thereof | |
CN117417431A (en) | Polypeptides with agonistic activity on GLP-1, glucagon and GIP receptor and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 544216 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2534748 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004249329 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006515545 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004249329 Country of ref document: AU Date of ref document: 20040618 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004249329 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004737019 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004737019 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007004619 Country of ref document: US Ref document number: 10561304 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10561304 Country of ref document: US |